Citigroup Upgrades Bioage Labs to Buy, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.
Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.